Navigation Links
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
Date:4/23/2013

NEW YORK, April 23, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased Incyte Corporation ("Incyte" or the "Company") (NasdaqGS: INCY) stock between April 26, 2012 and August 1, 2012 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

For more information, click here: http://zlk.9nl.com/incyte-incy/.  

According to the complaint, Incyte's reported fourth quarter 2011 and first quarter 2012 sales were artificially inflated due to a large number of advanced-stage myelofibrosis patients being prescribed the drug upon FDA approval in November 2011--patients who had been too sick to participate in the clinical trials.

On August 2, 2012, Incyte disclosed that Jakafi sales growth had been much softer during the second quarter of 2012 than investors had been led to expect. Defendants also disclosed that many of the new patients prescribed Jakafi were so sick they would not have been eligible for the Phase III trial. Defendants conceded that while prescriptions to these patients had increased sales revenues, these were not revenues that would continue for the suggested three years on average that defendants claimed, as certain patients died. In response to these disclosures, the price of Incyte stock fell from its August 1, 2012 close of $24.92 per share to close at $19.57 per share on August 2, 2012.

If you suffered a loss in Incyte you have until May 6, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/incyte-incy/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington, D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (866) 367-6510
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. ICBS, Update for Shareholders.
3. NeoStems CEO Letter to Shareholders
4. Monsanto Attempts to Lockout Socially Responsible Shareholder at Annual Meeting
5. SPO Updates Shareholders on 2012 Corporate Strategy
6. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
7. Genesis Biopharma Issues Letter To Shareholders
8. Medical Marijuana Inc. Shareholder Update - PhytoSPHERE Systems, LLC
9. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Issues CEO Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)...  GenomOncology today announced the appointment of Joshua F. ... Dr. Coleman will oversee clinical content development and ... The GenomOncology software suite empowers molecular pathologists with a seamless ... decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 30, 2016 /PRNewswire/ -  Equicare Health Inc ., the ... recognized as one of the top 100 companies in ... listing that distinguishes the top digital health companies across ... step forward this year continually upgrading our product with ... base and team," says Len Grenier , CEO ...
(Date:11/30/2016)...   Merck , a leading science and technology ... set of agreements with Evotec AG, whereby Evotec AG ... reagents such as CRISPR and shRNA libraries. Combining access ... accelerated pathway to explore and identify new drug targets. ... new targets, a process that can be time- and ...
(Date:11/30/2016)... ... 2016 , ... With growth rates averaging more than 30% each year, Random42 ... to continuing their expansion in their new office space. The new office has a ... by the creative industries, so Random42 Scientific Communication will fit right in. , ...
Breaking Biology Technology:
(Date:11/14/2016)... 2016  xG Technology, Inc. ("xG" or the "Company") ... communications for use in challenging operating environments, announced its ... Management will hold a conference call to discuss these ... Time (details below). Key Recent Accomplishments ... binding agreement to acquire Vislink Communication Systems. The purchase ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
Breaking Biology News(10 mins):